Impact of ultra-long sirolimus-eluting stents on coronary artery lesions: one-year results of real-world FLEX-LONG Study.

Autor:	Pamidimukkala V; Department of Neurology, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Polavarapu AR; Department of Medicine, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Polavarapu NR; Department of Medicine, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Gangasani S; Department of Medicine, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Gali D; Department of Medicine, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Bolinera SV; Department of Medicine, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Byrapaneni S; Department of Medicine, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India., Polavarapu RS; Department of Cardiology, Lalitha Super Specialities Hospital Pvt. Ltd., Heart and Brain Center, Kothapet, India - drpvraghav@gmail.com.
Jazyk:	angličtina
Zdroj:	Minerva medica [Minerva Med] 2020 Dec; Vol. 111 (6), pp. 529-535. Date of Electronic Publication: 2020 Apr 22.
DOI:	10.23736/S0026-4806.20.06333-8
Abstrakt:	Background: The FLEX-LONG study assessed the safety and clinical outcomes of ultra-long (44 mm/48 mm) biodegradable polymer-coated Supraflex (Sahajanand Medical Technology Pvt. Ltd., Surat, India) sirolimus-eluting stents (SES) in real-world patients with complex, long coronary artery lesions. Methods: It was an investigator-initiated, retrospective, non-randomized, observational and single-center study, which evaluated one-year results of 141 patients who had undergone implantation of at least one ultra-long (44 mm/48 mm) Supraflex SES. The incidence of major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR), at one-year follow-up was considered as primary outcome. Stent thrombosis was analyzed as a safety outcome. Results: The mean age of the study population was 56.2±9.6 years and 78.0% (110/141) patients were male. The study analyzed high risk patients, including 62 (44.0%) hypertensive and 60 (42.6%) diabetic patients. Total 147 target lesions were treated, including 25 (17.0%) total occlusions. Total 51 (34.7%) and 96 (65.3%) Supraflex SES of 44 mm and 48 mm were implanted, respectively. Average stent length and diameter were 46.6±1.9 mm and 3.4±0.2 mm, respectively. One-year follow-up was obtained in 100% of patients. There was one probable stent thrombosis after three weeks. At one-year follow-up, 99.3% of patients remained event free. Conclusions: The results of the FLEX-LONG study support the use of ultra-long (44 mm/48 mm) Supraflex SES, in the treatment of high-risk real-world patients. The stent appeared to be safe and effective at one-year with low clinical events in complex, long coronary artery lesions.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu